Endo Par v. BPI Labs & Belcher: Adrenalin® Epinephrine Patent Case Settled in 287 Days
Endo Par Innovation Company, Par Pharmaceutical, and Par Sterile Products brought an infringement action against BPI Labs and Belcher Pharmaceuticals over two patents protecting Adrenalin® epinephrine injection formulations. The Florida Middle District case closed after 287 days via a negotiated settlement, with all claims dismissed without prejudice and each party bearing its own legal costs.
Epinephrine Injection Patent Battle Ends in Negotiated Exit
Filed on 29 August 2023 in the Florida Middle District Court, this infringement action saw Endo Par Innovation Company, LLC, Par Pharmaceutical, Inc., and Par Sterile Products, LLC (collectively Endo) assert two patents — US9119876B1 and US9295657B1 — against BPI Labs, LLC and Belcher Pharmaceuticals, LLC. The asserted patents cover Adrenalin® epinephrine injection formulations, specifically the 1 mg/mL injectable solution and the 30 mg/30 mL vial presentation, a critical emergency-use pharmaceutical product.
The case closed on 11 June 2024, 287 days after filing, pursuant to a stipulated dismissal under Federal Rules of Civil Procedure 41(a)(1) and 41(c). The parties reached a negotiated settlement and agreed to dismiss all claims and defences without prejudice, with each side bearing its own attorneys’ fees and costs. The without-prejudice designation means Endo retains the theoretical option to re-file claims on these patents against Belcher in the future, should commercial circumstances change.
A resolution within 287 days is notably swift for a multi-patent pharmaceutical infringement dispute, suggesting the parties identified a commercial path to settlement before substantial litigation milestones — such as claim construction or summary judgment — were reached. The specific terms of the underlying settlement agreement are confidential and not reflected in the public record, leaving the nature of any licensing arrangement, market access agreement, or other commercial terms unknown. The mutual cost-bearing provision indicates neither party extracted a clear litigation concession from the other.
Filing to Dismissed without Prejudice in 287 days
287 days — below the median ANDA patent litigation duration in U.S. district courts, suggesting early settlement momentum
Dismissed without prejudice: what the settlement exit means for both parties
Rule 41 stipulated dismissal — no merits adjudicated
Under FRCP 41(a)(1) and 41(c), parties may jointly stipulate to dismiss an action without a court merits ruling. Here, Endo and Belcher filed such a stipulation following a private settlement agreement. No court finding was made on infringement, validity, or enforceability of US9119876B1 or US9295657B1 — the patents remain fully intact and enforceable.
No merits ruling — patents intactWithout prejudice: the door stays open for Endo
A dismissal without prejudice does not bar the plaintiff from refiling claims on the same patents against the same or different defendants in the future. This stands in contrast to a dismissal with prejudice, which would extinguish those specific claims permanently. The public record confirms the without-prejudice designation, meaning Endo’s enforcement rights on US9119876B1 and US9295657B1 are preserved. The private settlement terms governing Belcher’s conduct remain confidential.
Enforcement rights preservedEndo exits with patents unscathed and settlement secured
Endo retains full ownership and enforceability of both Adrenalin® patents. No validity or infringement finding was made that could be used defensively in future proceedings. The settlement — whose terms are undisclosed — likely reflects a commercial arrangement satisfactory to Endo, given the plaintiff-side decision to dismiss. The mutual cost-bearing clause suggests no material litigation leverage was ceded.
IP position unchangedBelcher exits litigation but faces ongoing patent risk
Belcher Pharmaceuticals and BPI Labs avoided an adverse merits ruling, which would have been valuable precedent. However, the without-prejudice dismissal means Endo could re-engage if Belcher’s commercial activities shift or a settlement term is breached. Companies in the epinephrine injection space should note that US9119876B1 and US9295657B1 remain active enforcement vehicles for Endo’s Adrenalin® franchise.
Re-filing risk persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Endo Par Innovation Company, LLC | Company | Pharmaceutical IP holding and manufacturing entities — holders of US9119876B1 and US9295657B1 (Adrenalin®)Search in Eureka ↗ |
| Co-Plaintiff | Par Pharmaceutical, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Par Sterile Products, LLC | Company | Search in Eureka ↗ |
| Defendant | BPI Labs, LLC | Company | BPI Labs, LLC and Belcher Pharmaceuticals, LLC — pharmaceutical manufacturers targeting the epinephrine injection marketSearch in Eureka ↗ |
| Co-Defendant | Belcher Pharmaceuticals, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Aziz Burgy | Attorney | Counsel for Endo Par Innovation Company, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Chad A. Landmon | Attorney | Counsel for Endo Par Innovation Company, LLCSearch in Eureka ↗ |
| Plaintiff counsel | John Gabriel Woodlee | Attorney | Counsel for Endo Par Innovation Company, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Matthew J. Becker | Attorney | Counsel for Endo Par Innovation Company, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Michael E. Lockamy | Attorney | Counsel for Endo Par Innovation Company, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Ricardo S. Camposanto | Attorney | Counsel for Endo Par Innovation Company, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Robert Troy Smith | Attorney | Counsel for Endo Par Innovation Company, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Axinn, Veltrop & Harkrider LLP | Law Firm | Representing Endo Par Innovation Company, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Bedell, Dittmar, DeVault, Pillans & Coxe PA | Law Firm | Representing Endo Par Innovation Company, LLCSearch in Eureka ↗ |
| Defendant counsel | Bonnie Fletcher | Attorney | Counsel for BPI Labs, LLCSearch in Eureka ↗ |
| Defendant counsel | John Habibi | Attorney | Counsel for BPI Labs, LLCSearch in Eureka ↗ |
| Defendant counsel | Jonathan Davies | Attorney | Counsel for BPI Labs, LLCSearch in Eureka ↗ |
| Defendant counsel | Jordan Landers | Attorney | Counsel for BPI Labs, LLCSearch in Eureka ↗ |
| Defendant counsel | Mindi M. Richter | Attorney | Counsel for BPI Labs, LLCSearch in Eureka ↗ |
| Defendant counsel | Sanya Sukduang | Attorney | Counsel for BPI Labs, LLCSearch in Eureka ↗ |
| Defendant counsel | Taras A. Gracey | Attorney | Counsel for BPI Labs, LLCSearch in Eureka ↗ |
| Defendant law firm | Cooley LLP | Law Firm | Representing BPI Labs, LLCSearch in Eureka ↗ |
| Defendant law firm | JMT Legal Services, LLC | Law Firm | Representing BPI Labs, LLCSearch in Eureka ↗ |
| Defendant law firm | Shumaker, Loop & Kendrick, LLP | Law Firm | Representing BPI Labs, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Florida Middle District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal language — ‘dismissed without prejudice, with each party to bear its own attorneys’ fees and costs’ — is a standard Rule 41 exit that carries no merits weight. No court finding was made on infringement or patent validity. The equal cost allocation is consistent with a balanced negotiated resolution rather than a capitulation by either side. The absence of a with-prejudice designation is significant: it preserves Endo’s ability to re-assert these patents if the commercial relationship or market conditions change.
US9119876B1 & US9295657B1 — Adrenalin® Epinephrine Injection Formulations
US9119876B1 and US9295657B1 both cover formulations and methods related to Adrenalin® epinephrine injection — a critical emergency-use pharmaceutical administered for anaphylaxis, cardiac arrest, and other acute conditions. The patents protect specific aspects of the 1 mg/mL injectable solution and the 30 mg/30 mL vial presentation (equivalent to 1 mg/mL). Application numbers US14/657990 and US14/818121 suggest filings in the 2015 timeframe, with the granted B1 designations confirming these issued without reexamination amendments.
Epinephrine injection is a high-stakes pharmaceutical segment — Adrenalin® has faced sustained generic competition pressure. Endo’s willingness to pursue litigation against BPI Labs and Belcher Pharmaceuticals signals active enforcement of these formulation patents as a commercial moat. For competitors, the existence of two overlapping patents covering both single-dose and multi-dose vial presentations creates a layered IP barrier that is difficult to design around without affecting the core therapeutic profile. Any party pursuing an ANDA or biosimilar pathway referencing Adrenalin® should treat these patents as primary clearance targets.
Should you run an FTO analysis against US9119876B1 and US9295657B1?
Any pharmaceutical company, CDMO, or ANDA filer developing or manufacturing an epinephrine injection product at 1 mg/mL — in either single-dose or 30 mL multi-dose vial formats — should conduct a freedom-to-operate analysis against US9119876B1 and US9295657B1 before IND filing, ANDA submission, or commercial launch. The without-prejudice dismissal in this case confirms Endo’s continued enforcement intent. R&D teams working on injectable epinephrine formulations should also assess the prosecution history of both patents for claim scope signals.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US9119876B1 and US9295657B1 against your product specifications, identify prior art that may support validity challenges, and surface related Endo family members that may present additional clearance requirements. Automated citation analysis and claim charting tools accelerate the process, enabling your IP team to deliver a defensible FTO opinion ahead of regulatory milestones rather than reactively after litigation is filed.
Run a freedom-to-operate analysis on US9119876B1 to assess your product’s exposure
Run FTO in Eureka →Similar Epinephrine Injection Patent Cases in U.S. District Courts
Explore comparable pharmaceutical formulation patent disputes involving injectable epinephrine and ANDA-related infringement actions in U.S. district courts.
What this case signals for the epinephrine injection IP landscape
Pharmaceutical companies targeting branded epinephrine injection markets face active patent enforcement from Endo’s Adrenalin® portfolio — and swift settlement is not a guarantee of immunity.
Both patents remain live enforcement tools for Endo
Neither US9119876B1 nor US9295657B1 was challenged on validity or infringement merits. The without-prejudice exit leaves them fully enforceable. Any competitor developing a 1 mg/mL epinephrine injectable product should treat these patents as active risk vectors and conduct a formal FTO analysis before regulatory submission or product launch.
Swift settlement signals commercial deal, not patent weakness
The 287-day resolution — before any substantive court rulings — is consistent with a commercially negotiated arrangement rather than a weakness in Endo’s patent position. Patent attorneys advising clients in the injectable epinephrine space should not interpret the early exit as an indication that these patents are vulnerable to invalidity or non-infringement challenges.
Endo v BPI — key questions answered
Endo Par Innovation, Par Pharmaceutical, and Par Sterile Products asserted US9119876B1 and US9295657B1 — both covering Adrenalin® epinephrine injection formulations at 1 mg/mL, including the 30 mg/30 mL multi-dose vial presentation. The case was filed in Florida Middle District Court on 29 August 2023.
A dismissal without prejudice under FRCP 41 means Endo retains the right to re-file infringement claims on US9119876B1 and US9295657B1 against Belcher or BPI Labs in the future. No merits ruling was made on infringement or patent validity, so the patents remain fully enforceable. It contrasts with a with-prejudice dismissal, which would bar re-filing those specific claims.
No. The case was resolved via a stipulated dismissal under FRCP 41(a)(1) and 41(c) following a private settlement agreement. The court made no finding on infringement or the validity of US9119876B1 or US9295657B1. Both patents remain intact and can continue to be enforced by Endo.
A 287-day resolution is notably swift for a multi-patent pharmaceutical infringement action. This timeline is consistent with the parties reaching a commercial settlement before substantive litigation milestones such as Markman hearings or dispositive motions. It suggests both sides identified mutually acceptable business terms early in the litigation, though the specific settlement terms remain confidential.
Yes. The without-prejudice dismissal in this case preserves Endo’s enforcement position on both patents. Companies developing or manufacturing epinephrine injection products — particularly at 1 mg/mL in multi-dose vial formats — should conduct a formal FTO analysis against US9119876B1 and US9295657B1 before ANDA submission or product launch. The prosecution history of these patents should also be reviewed for claim scope boundaries.
PatSnap Eureka searches patents and litigation data to answer instantly.